¼¼°èÀÇ ±âÁú Ç÷°ü ºÐȹ ½ÃÀå
Stromal Vascular Fraction
»óǰÄÚµå : 1765259
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 214 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,195,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,585,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

±âÁú Ç÷°ü ºÐȹ ¼¼°è ½ÃÀåÀº 2030³â±îÁö 1¾ï 2,780¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 9,820¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ±âÁú Ç÷°ü ºÐȹ ¼¼°è ½ÃÀåÀº 2024³âºÎÅÍ 2030³â±îÁö CAGR 4.5%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 1¾ï 2,780¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ºÐ¸® Á¦Ç°Àº CAGR 4.3%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 9,950¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÈíÀÎ Á¦Ç° ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 5.2%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 3,230¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 5.6%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ±âÁú Ç÷°ü ºÐȹ ½ÃÀåÀº 2024³â¿¡ 3,230¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGR 5.6%·Î 2030³â±îÁö ¿¹Ãø ½ÃÀå ±Ô¸ð 970¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 3.7%¿Í 4.0%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 4.3%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ±âÁú Ç÷°ü ºÐȹ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

±âÁú Ç÷°ü ºÐȹ(SVF)Àº Áö¹æÈíÀÔ¼ú·Î äÃëÇÑ Áö¹æÁ¶Á÷ À¯·¡ÀÇ ´Ù¾çÇÑ ¼¼Æ÷ Áý´ÜÀ¸·Î, Áö¹æÀ¯·¡ Áٱ⼼Æ÷(ADSC), ³»ÇÇ(Ç÷°ü)¼¼Æ÷, ¸é¿ª¼¼Æ÷, ±âŸ ¼¼Æ÷ ¼ººÐ µî ¿©·¯ Á¾·ùÀÇ ¼¼Æ÷°¡ dzºÎÇÏ°Ô È¥ÇյǾî ÀÖ½À´Ï´Ù. SVF¸¦ ºÐ¸®ÇÏ´Â °úÁ¤¿¡¼­ Áö¹æÁ¶Á÷À» È¿¼Ò·Î ¼ÒÈ­ÇÑ ÈÄ ¿ø½ÉºÐ¸®ÇÏ¿© Áö¹æ¼¼Æ÷(Áö¹æ¼¼Æ÷)¿¡¼­ ¼¼Æ÷ ºÐȹÀ» ºÐ¸®Çϰí, SVF´Â ÇöÀç ¿¬ºÎÁ¶Á÷ÀÇ È¸º¹À» ÃËÁøÇÏ´Â ¹Ì¿ë ½Ã¼úºÎÅÍ ¸¸¼ºÃ¢»ó Ä¡·á±îÁö ´Ù¾çÇÑ ºÐ¾ß¿¡¼­ Ȱ¿ëµÇ°í ÀÖ½À´Ï´Ù. ¿¬ºÎÁ¶Á÷ÀÇ È¸º¹À» ÃËÁøÇÏ´Â ¹Ì¿ë ½Ã¼úºÎÅÍ ¸¸¼º »óó, °ñ°üÀý¿°, ½ÉÇ÷°üÁúȯÀÇ Ä¡·á¿Í °°Àº º¸´Ù º¹ÀâÇÑ ÀÓ»ó ½Ã³ª¸®¿À¿¡ À̸£±â±îÁö ´Ù¾çÇÑ Ä¡·á¿¡ÀÇ Àû¿ëÀÌ °ËÅäµÇ°í ÀÖ½À´Ï´Ù.

SVFÀÇ ÀÓ»ó Ä¡·á ÀáÀç·ÂÀº ÃÖ¼Òħ½ÀÀû ÃßÃâ °úÁ¤°ú ¼¼Æ÷ Àç»ý ´É·ÂÀ¸·Î ÀÎÇØ ¾öû³­ ÀáÀç·ÂÀ» °¡Áö°í ÀÖÀ¸¸ç, SVF¿¡ ´ëÇÑ ¿¬±¸°¡ Å©°Ô È®´ëµÇ¾î Ä¡À¯ °úÁ¤À» °­È­ÇÏ°í ¿°ÁõÀ» °¨¼Ò½ÃŰ´Â µ¥ ÀÖ¾î À¯¸ÁÇÑ °á°ú¸¦ º¸¿©ÁÖ°í ÀÖ½À´Ï´Ù. °ÅºÎ¹ÝÀÀÀ̳ª À¯ÇØÇÑ ¸é¿ª¹ÝÀÀÀÇ À§ÇèÀ» ÃÖ¼ÒÈ­ÇÏ¿© ´Ù¸¥ ÀÌ½Ä °¡´ÉÇÑ Àç·á¿¡ ºñÇØ Å« ÀÌÁ¡À» Á¦°øÇÕ´Ï´Ù. ÀÌ ºÐ¾ßÀÇ ÃÖ±Ù ¹ßÀüÀº SVF ³» ¼¼Æ÷ÀÇ ¼öÀ²°ú »ýÁ¸À²À» ³ôÀ̱â À§ÇÑ ºÐ¸® ±â¼úÀÇ °³¼±°ú SVF ³» ´Ù¾çÇÑ ¼¼Æ÷ À¯ÇüÀÇ Æ¯ÀÌÀû ¿ªÇÒ¿¡ ´ëÇÑ ÀÌÇØÀÇ ÁõÁø¿¡ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ °³¼±Àº Àç»ýÀÇ·á¿¡¼­ SVFÀÇ Ä¡·á °¡´É¼ºÀ» ±Ø´ëÈ­ÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇϸç, ÇöÀç ÁøÇà ÁßÀÎ °úÇÐ ¿¬±¸ÀÇ ÁÖ¿ä ºÐ¾ßÀÔ´Ï´Ù.

SVF ½ÃÀåÀÇ ¼ºÀåÀº ¼¼Æ÷ ºÐ¸® ±â¼úÀÇ ¹ßÀü°ú Àç»ýÀÇ·á¿¡ ´ëÇÑ ÀÌÇØÀÇ Áõ°¡ µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. »ý¸í°øÇÐ ¿¬±¸¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡´Â SVF ±â¹Ý Ä¡·áÀÇ ±¤¹üÀ§ÇÑ Ã¤Åÿ¡ ÇʼöÀûÀÎ º¸´Ù È¿À²ÀûÀ̰í È®Àå °¡´ÉÇÑ Ã³¸® ±â¼úÀÇ °³¹ßÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÃÖ¼Òħ½ÀÀû ¹Ì¿ë ¹× Ä¡·á ½Ã¼ú¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â SVFÀÇ º¸±Þ¿¡ Å©°Ô ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¹Ì¿ë ¹× Àç°Ç Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä´Â Àþ¾î º¸À̰í ÀþÀ½À» À¯ÁöÇÏ·Á´Â »ç¶÷µéÀÇ ²÷ÀÓ¾ø´Â ¿­¸ÁÀ¸·Î ÀÎÇØ °è¼Ó Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ±âÁú Ç÷°ü ºÐȹ(SVF) Ä¡·á¹ý°ú °°Àº °ü·Ã ½ÃÀå¿¡ ÃæºÐÇÑ ±âȸ¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù. ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ© ¶ÇÇÑ ÀÌ·¯ÇÑ Çõ½ÅÀûÀÎ Ä¡·á¹ýÀÇ ÀÓ»óÀû »ç¿ë¿¡ ´ëÀÀÇÒ ¼ö ÀÖµµ·Ï ÁøÈ­Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ÀÓ»ó½ÃÇè ¹× Àû¿ëÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÏ¹Ý Àα¸ÀÇ °í·ÉÈ­¿Í ÇÔ²² SVF·Î Ä¡·áÇÒ ¼ö ÀÖ´Â ÅðÇ༺ ÁúȯÀÇ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ´ë»ó ȯÀÚ±ºÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿ä¼ÒµéÀÌ º¹ÇÕÀûÀ¸·Î ÀÛ¿ëÇÏ¿© ¹ÙÀÌ¿À¸ÞµðÄà ºÐ¾ß¿¡¼­ SVF ºÐ¾ßÀÇ Áö¼ÓÀûÀÎ ¼ºÀå°ú ¹ßÀüÀ» ÃËÁøÇÏ´Â Áß¿äÇÑ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù.

ºÎ¹®

Á¦Ç° À¯Çü(ºÐ¸® Á¦Ç°, ÈíÀÎ Á¦Ç°, ÀÌ½Ä Á¦Ç°), ¿ëµµ(¿¬Á¶Á÷, ¹Ì¿ë, Á¤Çü¿Ü°ú, ±âŸ ¿ëµµ), ÃÖÁ¾ ¿ëµµ(º´¿ø, Àü¹® Ŭ¸®´Ð, Áٱ⼼Æ÷ÀºÇà/¿¬±¸¼Ò, ±âŸ ÃÖÁ¾ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM ¹× ¾÷°èº° SLM Äõ¸®¸¦ µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Stromal Vascular Fraction Market to Reach US$127.8 Million by 2030

The global market for Stromal Vascular Fraction estimated at US$98.2 Million in the year 2024, is expected to reach US$127.8 Million by 2030, growing at a CAGR of 4.5% over the analysis period 2024-2030. Isolation Products, one of the segments analyzed in the report, is expected to record a 4.3% CAGR and reach US$99.5 Million by the end of the analysis period. Growth in the Aspiration Products segment is estimated at 5.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$32.3 Million While China is Forecast to Grow at 5.6% CAGR

The Stromal Vascular Fraction market in the U.S. is estimated at US$32.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$9.7 Million by the year 2030 trailing a CAGR of 5.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.7% and 4.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.3% CAGR.

Global Stromal Vascular Fraction Market - Key Trends and Drivers Summarized

Stromal Vascular Fraction (SVF) is a diverse cell population derived from adipose (fat) tissue, which is harvested through liposuction procedures. SVF contains a rich mix of several cell types including adipose-derived stem cells (ADSCs), endothelial (blood vessel) cells, immune cells, and other cellular components. This cell mixture is particularly noted for its regenerative properties, making it a promising tool in regenerative medicine and tissue engineering. The process of isolating SVF involves enzymatic digestion of adipose tissue followed by centrifugation to separate the cellular fraction from adipocytes (fat cells). SVF is currently being explored in a variety of therapeutic applications ranging from cosmetic procedures enhancing soft tissue repair to more complex clinical scenarios like treating chronic wounds, osteoarthritis, and cardiovascular diseases.

The potential of SVF in clinical therapies is vast due to its minimally invasive extraction process and the regenerative capabilities of the cells it contains. Research in SVF has expanded significantly, showing promising results in enhancing healing processes and reducing inflammation. The autologous nature of SVF (derived from the patient’s own body) minimizes the risk of rejection and adverse immune reactions, a significant advantage over other transplantable materials. Recent advancements in the field have aimed at refining the isolation techniques to increase the yield and viability of cells in SVF, and enhancing the understanding of the specific roles of different cell types within the fraction. These improvements are critical in maximizing the therapeutic potential of SVF in regenerative medicine, making it a key area of ongoing scientific research.

The growth in the SVF market is driven by several factors, including advancements in cell isolation technologies and a deepening understanding of regenerative medicine. Increased investment in biotechnology research has propelled the development of more efficient and scalable processing techniques, which are crucial for the wider adoption of SVF-based therapies. Additionally, the growing demand for minimally invasive cosmetic and therapeutic procedures has significantly contributed to the popularity of SVF. The demand for aesthetic & reconstructive therapies continues to grow owing to the never-ending desire of people to look younger and retain youthful appearance, while creating ample opportunities for related markets such as stromal vascular fraction (SVF) treatment method. Regulatory frameworks are also evolving to better accommodate the clinical use of such innovative therapies, thereby encouraging more clinical trials and applications. Moreover, as the general population ages, there is an increasing prevalence of degenerative diseases which can potentially be treated with SVF, thus expanding the target demographic. Together, these elements are key drivers promoting the sustained growth and development of the SVF sector in the biomedical field.

SCOPE OF STUDY:

The report analyzes the Stromal Vascular Fraction market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Isolation Products, Aspiration Products, Transfer Products); Application (Soft Tissue, Cosmetic, Orthopedic, Other Applications); End-Use (Hospitals, Specialty Clinics, Stem Cell Banks/Laboratories, Other End-Uses)

Geographic Regions/Countries:

World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Rest of Europe; Asia-Pacific; Rest of World.

Select Competitors (Total 25 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â